Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24

Rhea-AI Summary

MIAMI, March 19, 2021 – Longeveron (NASDAQ: LGVN), a biotechnology company focused on cellular therapies for aging-related and life-threatening conditions, will present at the Q1 Virtual Investor Summit. The event runs from March 23-25, 2021, with Longeveron's presentation scheduled for March 24 at 10:00 am ET. This summit connects smallcap companies with investors, featuring over 100 companies and 300 investors. Longeveron is advancing its lead therapy, LOMECEL-B, aimed at conditions like Aging Frailty and Alzheimer’s disease. For more details, visit longeveron.com.

MIAMI, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Green, CEO of Longeveron, will be presenting at the Q1 Virtual Investor Summit.

Event	Q1 Investor Summit
Date	March 23-25, 2021
Presentation	March 24 @ 10:00 am ET
Location	Small Cap Conference ZOOM Link

About The Investor Summit
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors. 

To request complimentary investor registration: please visit our website at www.investorsummitgroup.com

About Longeveron

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.

Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: lgvn@crescendo-ir.com

Investor Summit Contact: 
Brittney Blocker at brittney@investorsummitgroup.com

Wire Service Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
Editor@InvestorWire.com

FAQ

When is Longeveron's presentation at the Q1 Investor Summit?

Longeveron's presentation is scheduled for March 24, 2021, at 10:00 am ET.

What is the Q1 Investor Summit?

The Q1 Investor Summit is a virtual conference connecting smallcap and microcap companies with investors, featuring over 100 companies and 300 investors.

What are the dates for the Q1 Investor Summit?

The Q1 Investor Summit will take place from March 23-25, 2021.

Where can I find more information about Longeveron?

More information about Longeveron can be found on their website at www.longeveron.com.

What is the focus of Longeveron's research?

Longeveron focuses on developing cellular therapies for chronic aging-related and life-threatening conditions, including Aging Frailty and Alzheimer’s disease.